Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 1, 2011, Pages

  Nglazi, Mweete D ^a,b   Lawn, Stephen D ^a,c   Kaplan, Richard ^a   Kranzer, Katharina ^a,c   Orrell, Catherine ^a   Wood, Robin ^a   Bekker, Linda Gail ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; COMMUNITY CARE; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCALE UP; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMMUNITY HEALTH SERVICES; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; PATIENT DROPOUTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78650688259     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ff0bdc     Document Type: Article

References (19)

1. World Health Organisation. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector. Progress Report 2009. Geneva, Switzerland: Wolrd Health Organization; 2010. Available at: http://www.who.int/ hiv/pub/tuapr-2009-en.pdf. Accessed 12 January, 2010.
2. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224.
3. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
4. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
5. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4:e298.
6. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 20 2010;24:563-572.
7. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008;22:2303-2311.
8. Sanne IM, Westreich D, Macphail AP, et al. Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc. 2009;12:38.
9. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral programme in South Africa: implications for programme design. AIDS. 2005;19:2141-2148.
10. Bekker LG, Myer L, Orrell C, et al. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 conecutive years in Gugulethu, South Africa. S Afr Med J. 2006;96:315-320.
11. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for programme evaluation. Clin Infect Dis. 2006;43:770-776.
12. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23:335-342.
13. Lawn SD, Kaplan R, Wood R, Bekker LG. Promoting retention in care: an effective model in an antiretroviral treatment service in South Africa. Clin Infect Dis. 2007;45:803.
14. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717-1725.
15. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ. 2008;86:678-687.
16. Brinkhof MWG, Dabis F, Myer L, et al. Early loss of HIv-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-567.
17. Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009; 14:523-531.
18. Barth RE, Van Der Loeff MF, Schuurman R, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10:155-166.
19. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1-15.